Literature DB >> 19807594

Healthy year equivalents versus quality-adjusted life years: the debate continues.

Isabel Towers1, Anne Spencer, John Brazier.   

Abstract

The quality-adjusted life year makes a number of restrictive assumptions about the nature of one's preference over health. The healthy year equivalent was originally proposed over 10 years ago as a major theoretic advance on the quality-adjusted life year. This article reviews the theoretic, empiric and normative bases for the healthy year equivalent and quality-adjusted life year approaches to valuing health profiles that vary over time. Although critics have argued that the two-stage procedure proposed by the developers of healthy year equivalent is theoretically equivalent to a generalized time trade-off question, the notion of directly valuing a series of health states in a health profile has been an important contribution to the literature. Since then, new quality-adjusted life year approaches have been developed to combine health states that vary over time. However, these approaches have yet to be tested empirically. The empiric evidence comparing quality-adjusted life years with healthy year equivalents is equivocal, and the size and direction of difference is context specific. In some studies, no differences have been found. At the same time, where differences are observed, it is difficult to interpret the healthy year equivalent values as the gold standard since there is evidence of cognitive confusion in the answers being given to the valuations of complex health profiles. Based on the evidence to date, it is not clear that healthy year equivalents provide a better measure of preferences than quality-adjusted life years.

Entities:  

Year:  2005        PMID: 19807594     DOI: 10.1586/14737167.5.3.245

Source DB:  PubMed          Journal:  Expert Rev Pharmacoecon Outcomes Res        ISSN: 1473-7167            Impact factor:   2.217


  4 in total

1.  Response to letter to editor: Capturing disutility from waiting time.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

2.  Capturing disutility from waiting time.

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

3.  Quality-adjusted life years in macular oedema due to age-related macular degeneration, diabetes and central retinal vein occlusion: the impact of anti-VEGF agents in a tertiary centre in Greece.

Authors:  Nikolaos T Voutsas; Eleni Papageorgiou; Alexandra Tantou; Vassilis A Dimitriou; Evangelia E Tsironi; Maria Kotoula
Journal:  Int Ophthalmol       Date:  2022-04-13       Impact factor: 2.029

Review 4.  The role of patient preferences in cost-effectiveness analysis: a conflict of values?

Authors:  John E Brazier; Simon Dixon; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.